SRR4195694
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.400
- COAGULATION+0.330
- KRAS_SIGNALING_DN+0.300
- BILE_ACID_METABOLISM+0.280
- FATTY_ACID_METABOLISM+0.190
- PANCREAS_BETA_CELLS+0.170
- SPERMATOGENESIS+0.100
- APICAL_SURFACE+0.090
- CHOLESTEROL_HOMEOSTASIS+0.080
- COMPLEMENT+0.020
Top 10 suppressed
- PROTEIN_SECRETION-0.560
- E2F_TARGETS-0.470
- G2M_CHECKPOINT-0.450
- MITOTIC_SPINDLE-0.440
- MYC_TARGETS_V1-0.430
- UV_RESPONSE_DN-0.390
- TGF_BETA_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- ANDROGEN_RESPONSE-0.320
- GLYCOLYSIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-KQ-A41R-01A-21R-A352-07 | — | — | 0.878 |
| 2 | TCGA-49-4514-01A-21R-1858-07 | — | cohortA4 | 0.843 |
| 3 | SRR1316535 | GTEX | — | 0.840 |
| 4 | TCGA-49-AAR0-01A-21R-A39D-07 | — | cohortA3 | 0.838 |
| 5 | SRR8613724 | — | F | 0.838 |
| 6 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.835 |
| 7 | SJEPD030_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.826 |
| 8 | MNG339 | — | — | 0.823 |
| 9 | SRR1444460 | GTEX | — | 0.822 |
| 10 | SRR1332048 | GTEX | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |